US Stock MarketDetailed Quotes

ALGS Aligos Therapeutics

Watchlist
  • 0.820
  • -0.026-3.09%
Trading May 3 15:45 ET
61.51MMarket Cap-602P/E (TTM)

About Aligos Therapeutics Company

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Company Profile

SymbolALGS
Company NameAligos Therapeutics
Listing DateOct 16, 2020
Issue Price15.00
Founded2018
CEODr. Lawrence M. Blatt,PhD
MarketNASDAQ
Employees66
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address1 Corporate Drive,2nd floor
CitySouth San Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-800-466-6059
Websitehttp://www.aligos.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Lawrence M. Blatt,PhD
  • President, Chairman of the Board and Chief Executive Officer
  • 1.34M
  • Dr. Matthew W. McClure, M.D.
  • Executive Vice President and Chief Medical Officer
  • 837.72K
  • Julian A. Symons, D.Phil.
  • Executive Vice President and Chief Scientific Officer
  • 836.32K
  • Lesley Ann Calhoun
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • --
  • Dr. K. Peter Hirth, PhD
  • Independent Director
  • 60.40K
  • Carole L. Nuechterlein, J.D.
  • Independent Director
  • 12.90K
  • James Scopa
  • Independent Director
  • 67.90K
  • Dr. Bridget A. Martell, M.D.
  • Independent Director
  • 52.90K
  • Jack Bech Nielsen
  • Lead Independent Director
  • 93.40K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg